Together, we could monitored the molecular response of CML patients after TKI treatment by serially measure the level of BCR-ABL1 fusion transcript and T315I mutation was predominantly identified in most cases with TKI resistant. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.